相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy
Charles J. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer
Daniel C. Danila et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience
D. Olmos et al.
ANNALS OF ONCOLOGY (2009)
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
CANCER RESEARCH (2009)
Characterization of Circulating Tumor Cells by Fluorescence In Situ Hybridization
Joost F. Swennenhuis et al.
CYTOMETRY PART A (2009)
Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data
Howard I. Scher et al.
LANCET ONCOLOGY (2009)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven
Gerhardt Attard et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
Sunita R. Setlur et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Estimates of the cancer incidence and mortality in Europe in 2006
J. Ferlay et al.
ANNALS OF ONCOLOGY (2007)
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
G. Attard et al.
BRITISH JOURNAL OF CANCER (2006)
CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets
Tarek Hakki et al.
PHARMACOLOGY & THERAPEUTICS (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Aromatase inhibition: Translation into a successful therapeutic approach
J Geisler et al.
CLINICAL CANCER RESEARCH (2005)
The androgen axis in recurrent prostate cancer
JL Mohler et al.
CLINICAL CANCER RESEARCH (2004)
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
J Holzbeierlein et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases
WJ Allard et al.
CLINICAL CANCER RESEARCH (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration
O Smaletz et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
